Delving into the Latest Updates on Taprenepag isopropyl with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Taprenepag, Taprenepag isopropyl (USAN)

+ [3]

Target

EP2 x Opioid receptors

Mechanism

EP2 agonists(Prostanoid EP2 receptor agonists), Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Eye Diseases

Active Indication-

Inactive Indication

Glaucoma, Open-Angle

Originator Organization

Pfizer Inc.

Active Organization-

Inactive Organization

Pfizer Inc.

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC27H28N4O5S

InChIKeyNVPXUFQLKWKBHK-UHFFFAOYSA-N

CAS Registry1005549-94-9

View All Structures (2)

Background: Prostaglandin (PG) receptor agonists are the first-line eyedrop medication treatment for glaucoma. The pathophysiology of this disease is not completely known, and elevated intraocular pressure (IOP) is the key risk factor. The membranes of the axons (of the retinal ganglion cells) passing through the optic nerve (ON) head experience significant damage. Lipids are an essential component of the cell's membranes, and their profile changes owing to neurodegeneration. In this investigation, three agonists for distinct PG receptors were used to lower IOP and to determine their effect on the ON lipids. We utilized DBA/2J mice as a model of progressive IOP increase and C57BL/6J mice as a model of ON crush. Methods: DBA/2J and C57BL/6J mice were treated daily for 2 weeks with Latanoprost, PF-04217329, or Rivenprost. The IOP was measured every 2 days and pattern electroretinogram was conducted for DBA/2J throughout the study. Lipidomics of ONs were performed for each model and treatment group. Results: Of the tested compounds, Latanoprost and Rivenprost were the most effective agents decreasing IOP in DBA/2J mice. Triglyceride levels increased in the ONs of DBA/2J mouse model, but phosphatidylethanolamine levels underwent highest level changes in the C57BL/6J mouse model when treated with Latanoprost. Conclusions: Topical ocular FP- and EP4-receptor agonists appreciably lowered IOP in the DBA/2J mice representing pigmentary glaucoma. The observed changes in ON lipidomics in the different models of neurodegeneration suggest possible use of such measures in the development of more effective medicines for both IOP reduction and ON protection.

03 May 2022·Proceedings of the National Academy of SciencesQ1 · CROSS-FIELD

Agonists of prostaglandin E ₂ receptors as potential first in class treatment for nephronophthisis and related ciliopathies

Q1 · CROSS-FIELD

Article

Author: Saunier, Sophie ; Porée, Esther ; Delous, Marion ; Krug, Pauline ; Fila, Marc ; Salomon, Rémi ; Briseño-Roa, Luis ; Garcia, Hugo ; Viau, Amandine ; Serafin, Alice S. ; Sin-Monnot, Soraya ; Cagnard, Nicolas ; Lyonnet, Stanislas ; Billot, Katy ; Annereau, Jean-Philippe ; Del Nery, Elaine ; Benmerah, Alexandre ; Mahaut, Clémentine ; Roy, Stéphanie ; Silbermann, Flora ; Garfa-Traore, Meriem ; Birgy, Éléonore ; Antignac, Corinne ; Deleglise, Bérangère ; Rodriguez, Pamela C. ; Jabot-Hanin, Fabienne ; Mehraz, Manon ; Ceccarelli, Salomé ; Furio, Laetitia

Significance Juvenile nephronophthisis (NPH) is a renal ciliopathy due to a dysfunction of primary cilia for which no curative treatment is available. This paper describes the identification of agonists of prostaglandin E 2 receptors as a potential therapeutic approach for the most common NPHP1 -associated ciliopathies. We demonstrated that prostaglandin E 1 rescues defective ciliogenesis and ciliary composition in NPHP1 patient urine-derived renal tubular cells and improves ciliary and kidney phenotypes in our NPH zebrafish and Nphp1 −/− mouse models. In addition, Taprenepag alleviates the severe retinopathy observed in Nphp1 −/− mice. Finally, transcriptomic analyses pointed out several pathways downstream the prostaglandin receptors as cell cycle progression, extracellular matrix, or actin cytoskeleton organization. Altogether, our findings provide an alternative for treatment of NPH.

01 Apr 2019·British Journal of PharmacologyQ2 · MEDICINE

Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma

Q2 · MEDICINE

Review

Author: Brambilla, Stefania ; Impagnatiello, Francesco ; Almirante, Nicoletta ; Bastia, Elena ; Bergamini, Michael V W ; Kothe, Angela C ; Duquesroix, Brigitte

In patients with ocular hypertension or glaucoma, all treatments aim to lower intraocular pressure (IOP) by modulating aqueous humour (AH) production and/or uveoscleral and trabecular meshwork/Schlemm's canal AH drainage. PG analogues are considered to be the ‘gold standard’ treatment and are the most frequently used IOP‐lowering agents. Recent data support an important role for NO in regulating IOP. Thus, novel PG analogues carrying a NO‐donating moiety were recently advanced. Latanoprostene bunod (LBN) and NCX 470, NO‐donating derivatives of latanoprost and bimatoprost, respectively, are examples of such compounds. LBN ophthalmic solution, 0.024% (Vyzulta™), showed greater IOP‐lowering efficacy compared with that of Xalatan® (latanoprost ophthalmic solution, 0.005%) or 0.5% timolol maleate in clinical settings. NCX 470 was found to be more effective than bimatoprost in animal models of ocular hypertension and glaucoma. Selective EP2 receptor agonists (i.e. taprenepag isopropyl, omidenepag isopropyl and aganepag isopropyl) and non‐selective prostanoid receptor agonists (i.e. ONO‐9054, sepetaprost isopropyl) that concomitantly stimulate FP and EP3 receptors have also been shown to hold promise as effective IOP‐lowering agents.Linked ArticlesThis article is part of a themed section on Eicosanoids 35 years from the 1982 Nobel: where are we now? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc

100 Deals associated with Taprenepag isopropyl

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09969	-	-	DB12623

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glaucoma, Open-Angle	Phase 2	US	Pfizer Inc.	11 Dec 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00934089 (CTgov)	Phase 2	Glaucoma, Open-Angle	31	Taprenepag+Latanoprost (Taprenepag+Latanoprost)	hrofqkdqhc(nskimzevcx) = sowjfbpewv ffhtghtecz (racwawaxzq, cnfneqccti - spsfmqyaos) View more	-	03 May 2021
				Taprenepag+Latanoprost (Taprenepag+Latanoprost Vehicle)	hrofqkdqhc(nskimzevcx) = limbrlgxsn ffhtghtecz (racwawaxzq, yxkcuqujdw - zahrearsrd) View more
NCT00934089 (ARVO2011)	Phase 2	-	30	Taprenepag Isopropyl 0.01%	(egvkfzolni) = cdznhxjtgz jboejddafq (ckgtkzawoy ) View more	-	01 Apr 2011
				Taprenepag Isopropyl 0.01% + Latanoprost 0.005%	(egvkfzolni) = frtuzabgvo jboejddafq (ckgtkzawoy ) View more
NCT00572455 (ARVO2010)	Phase 1	Ocular Hypotension	67	PF-04217329 0.0025%	fbcdjwbiys(qixcuaisnr) = ufrasqsoyf ccedzgbkqg (bgxpnwxngh )	Positive	01 Apr 2010
				PF-04217329 0.005%	fbcdjwbiys(qixcuaisnr) = lweipqzgcx ccedzgbkqg (bgxpnwxngh )